ILS-920

ILS-920 is a synthetic small molecule and a nonimmunosuppressive analog of rapamycin, developed as a neuroprotectant for the treatment of stroke. It acts primarily by binding selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels. Unlike traditional rapalogs, it exhibits reduced immunosuppressive activity but retains potent neuroprotective effects. In preclinical models, ILS-920 demonstrated significant protection against neuronal injury, reduction in postischemic inflammation, and promotion of regenerative markers following stroke. The drug completed phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics after intravenous administration in healthy adults; however, further development appears to have been discontinued[1][3][4][5].

Other names

ILS 920ILS920ILS-920WAY-265920WAY265920WAY 265920